Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
These appetite-suppressing treatments can help you manage hunger, support metabolic health, and make lasting progress
Nonetheless, these clinical trials were underpowered to detect rare events such as suicidal ideation and self-injurious behavior, and they systematically excluded patients with psychiatric comorbidities commonly seen in clinical settings
"So many of my patients are looking for natural solutions for GLP-1 support which is why I'm so proud of this breakthrough formulation
The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders
37 Small molecule GLP-1RAs are chemically synthesized, and compared to protein-based drugs, they generally have smaller molecular sizes
